Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

Prevision Policy Clips | FDA Commissioner Califf Highlights Patient Engagement Efforts At Digital Health Event

May 9, 2023

Prevision Policy Clips | CDC Overhaul Will Be Led By New Director: Walensky To Step Down

May 8, 2023

Sarepta DMD Advisory Committee Has High-Profile Audience: FDA Commissioner Pressed To Allow More Public Speakers During Senate PAHPA Reauthorization Hearing

May 5, 2023

Gene & Cell Therapy Postmarket Surveillance: “Lifelong” Follow-Up, Multi-Sponsor Registries Pique FDA Interest; Guidance Coming

May 5, 2023

Opill OC Non-Prescription Switch Unlikely To Win Committee Support Based On List Of FDA Concerns; New Study Plus “ACNU” Rule May Be Enough, But FDA May Prefer New Product – Or Sponsor

May 5, 2023

“Anti-Aging” R&D? One Drug To Prevent Many Diseases Is Possible, But Endpoints First Need Outside Work To Find Scientific Consensus, FDA’s Califf Says

May 5, 2023

Prevision Policy Clips | Intercept OCA For NASH: FDA Grants Three Waivers For Advisory Committee Members, Including Chair

May 5, 2023

NASH Drug Coverage Issues Trigger Memories Of Hepatitis C Among Payors; ICER Panel Unimpressed By Intercept’s OCA, Sees Madrigal Agent More Favorably

May 4, 2023

Prevision Policy Clips | FDA Commissioner Califf On Lilly’s Donanemab: An “Interesting Day” For Alzheimer’s

May 4, 2023

Decentralized Trials Are Here To Stay: FDA Draft Guidance Offers Ways To Reduce Variability In Data, Affirms Agency Support For The Approach

May 3, 2023

Prevision Policy Clips | Another Beta-Amyloid Therapy Shows Clinical Benefit In Alzheimer’s: Lilly Donanemab TRAILBLAZER-ALZ 2

May 3, 2023

HELP Hearing Showcases Bipartisan Interest In Generic Competition, PBM Reforms – And Lack Of Legislative Acumen From New Leadership; Votes Postponed Pending Upcoming CEO Hearing

May 2, 2023

Prevision Policy Clips | AstraZeneca/Sanofi RSV Antibody Nirsevimab Heads To Advisory Committee June 8

May 2, 2023

Long COVID PFDD Meeting Focuses On Trial Participation Considerations; FDA Hears Significant Risk Tolerance In Comments From Patients

May 1, 2023

AZ/Merck Lynparza Headed To Narrow First-Line Prostate Cancer Label After ODAC Supports FDA Push For BRCA-Only Use

May 1, 2023

Prevision Policy Clips | FDA RFI On Patient Experience Data Kicks Off PDUFA VII Process

May 1, 2023

Prevision Policy Clips | Nonclinical Biodistribution Gene Therapies Guidance Finalized By FDA

April 28, 2023

Value-Based Purchasing For Gene Therapies, PBM Transparency Are Points Of Interest At Energy & Commerce Health Subcommittee Hearing

April 27, 2023

Prevision Policy Clips | Medicaid Payment For Gene Therapies: Energy & Commerce Health Subcommittee Chair Guthrie Highlights Proposed Legislation

April 27, 2023

ODAC To Consider Restricting First-Line Use Of Lynparza In Metastatic Prostate Cancer To Patients with BRCA Mutations; “Possible Harm” To Those Without

April 26, 2023

Alzheimer’s Coverage Expansion: CMS Envisions Light Touch For Registry Once Leqembi Is “Fully” Approved

April 26, 2023

Prevision Policy Clips | Sanders/Cassidy Release Bipartisan PBM Transparency, Drug Pricing Reform Package

April 26, 2023

Advisory Committee Tracker: Landmark Meetings On DMD (Sarepta), NASH (Intercept), RSV (Pfizer) And OTC OC (Perrigo) Highlight Blockbuster May

April 25, 2023

Prevision Policy Clips | Paul Lee Is Acting Director Of FDA’s Division Of Neurology II

April 25, 2023

Prevision Policy Clips | Insulin Manufacturer CEOs, “Top Executives” From Major PBMs Will Testify May 10 At Senate HELP Insulin Affordability Hearing

April 24, 2023
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2023 Prevision Policy. All Rights Reserved. Privacy Policy